Below is a list of news items that were submitted to the news feed:
Featured Article
|
Below is a list of news items that were submitted to the news feed: Featured Article |
|
1-10 (8/7/10 - 9/5/10) 11-20 (5/15/10 - 8/5/10) 21-30 (4/4/10 - 5/14/10) 31-40 (3/12/10 - 3/31/10) 41-50 (3/1/10 - 3/12/10) 51-60 (2/4/10 - 2/17/10) 61-70 (1/13/10 - 2/3/10) 71-80 (12/26/09 - 1/11/10) 81-90 (11/17/09 - 12/23/09) 91-100 (10/11/09 - 11/16/09) 101-110 (9/28/09 - 10/10/09) 111-120 (8/25/09 - 9/20/09) 121-130 (7/5/09 - 8/24/09) 131-140 (6/3/09 - 6/27/09) 141-150 (4/21/09 - 5/18/09) 151-160 (4/3/09 - 4/20/09) 161-170 (3/20/09 - 4/2/09) 171-180 (2/19/09 - 3/14/09) 181-190 (2/6/09 - 2/18/09) 191-200 (1/9/09 - 2/3/09) 201-210 (12/26/08 - 1/8/09) 211-220 (12/13/08 - 12/26/08) 221-230 (11/26/08 - 12/12/08) 231-240 (11/18/08 - 11/25/08) 241-250 (10/24/08 - 11/17/08) 251-260 (10/2/08 - 10/22/08) 261-270 (9/15/08 - 10/2/08) 271-280 (8/28/08 - 9/12/08) 281-290 (7/23/08 - 8/27/08) 291-300 (6/23/08 - 7/19/08) 301-310 (6/6/08 - 6/20/08) 311-320 (4/22/08 - 6/6/08) 321-330 (3/17/08 - 4/21/08) 331-340 (2/22/08 - 3/11/08) 341-350 (2/15/08 - 2/22/08) 351-360 (1/30/08 - 2/15/08) 361-370 (1/17/08 - 1/29/08) 371-380 (1/5/08 - 1/17/08) 381-390 (12/11/07 - 1/3/08) 391-400 (11/27/07 - 12/9/07) 401-410 (10/20/07 - 11/26/07) 411-420 (10/3/07 - 10/19/07) 421-430 (9/8/07 - 10/2/07) 431-440 (8/21/07 - 9/7/07) 441-450 (8/1/07 - 8/20/07) 451-460 (7/11/07 - 7/30/07) 461-470 (6/22/07 - 7/8/07) 471-480 (6/3/07 - 6/21/07) 481-490 (5/15/07 - 6/1/07) 491-500 (4/29/07 - 5/14/07) 501-510 (4/11/07 - 4/27/07) 511-520 (4/2/07 - 4/11/07) 521-530 (3/19/07 - 4/2/07) 531-540 (2/22/07 - 3/19/07) 541-550 (2/13/07 - 2/21/07) 551-560 (2/1/07 - 2/12/07) 561-570 (12/12/06 - 2/1/07) 571-580 (9/9/06 - 12/12/06) 581-590 (6/24/06 - 8/31/06) 591-600 (5/4/06 - 6/22/06) 601-610 (2/17/06 - 5/2/06) 611-620 (1/7/06 - 2/17/06) 621-630 (12/8/05 - 1/6/06) 631-640 (11/27/05 - 12/7/05) 641-650 (11/12/05 - 11/26/05) 651-660 (10/12/05 - 11/8/05) 661-670 (9/20/05 - 10/11/05) 671-680 (8/30/05 - 9/16/05) 681-690 (8/10/05 - 8/29/05) 691-700 (7/13/05 - 8/10/05) 701-710 (6/8/05 - 7/12/05) 711-720 (5/18/05 - 6/2/05) 721-730 (4/19/05 - 5/12/05) 731-740 (4/4/05 - 4/18/05) 741-750 (3/8/05 - 3/31/05) 751-760 (2/23/05 - 3/7/05) 761-770 (2/6/05 - 2/22/05) 771-780 (1/20/05 - 2/6/05) 781-790 (1/3/05 - 1/19/05) 791-800 (11/29/04 - 12/28/04) 801-810 (10/24/04 - 11/28/04) 811-820 (9/20/04 - 10/21/04) 821-830 (8/16/04 - 9/19/04) 831-840 (7/26/04 - 8/5/04) 841-850 (6/30/04 - 7/23/04) 851-860 (6/11/04 - 6/30/04) 861-870 (5/10/04 - 6/11/04) 871-880 (4/30/04 - 5/10/04) 881-890 (4/18/04 - 4/29/04) 891-900 (2/25/04 - 4/14/04) 901-910 (10/28/03 - 2/19/04) 911-920 (9/30/03 - 10/28/03) 921-930 (7/14/03 - 9/27/03) 931-940 (5/7/03 - 7/14/03) 941-950 (4/15/03 - 5/6/03) 951-960 (2/14/03 - 4/13/03) 961-970 (1/20/03 - 2/12/03) 971-980 (1/6/03 - 1/17/03) 981-990 (10/16/02 - 12/25/02) 991-1000 (9/19/02 - 10/16/02) 1001-1001 (0/0/ - 0/0/) |
|
191. Panel likes Lilly drug but not for stroke patients http://www.wtop.com/?nid=111&sid=1591967 2009-02-03 15:05:24 Description: SILVER SPRING, Md. (AP) - A panel of government health experts said Tuesday a highly anticipated Eli Lilly blood thinner marks a significant advance over older treatments and should be approved. The nine members of the Food and Drug Administration's cardiology panel unanimously voted in favor of the company's anticlotting drug prasugrel. The FDA is not required to follow the advice of the panel, though it usually does. The positive recommendation marks a remarkable turnaround for a drug that some analysts worried might be derailed by troublesome side effects, including internal bleeding. FDA has been reviewing prasugrel for more than a year and has twice missed its own deadlines for making a decision on the drug. The agency |
|
192. Slices of living brain tissue are helping scientists identify new ... http://www.sciencecentric.com/news/article.php?q=09012440-slices-living-brain-tissue-are-helping-sci entists-identify-new-stroke-therapies 2009-01-24 12:03:03 Description: Slices of living human brain tissue are helping scientists learn which drugs can block the waves of death that engulf and engorge brain cells following a stroke. It's called anoxic depolarisation and it primarily results from the brain getting insufficient blood and oxygen after a stroke, says Dr Sergei Kirov, neuroscientist in the Medical College of Georgia Schools of Medicine and Graduate Studies. The brain uses about 20 percent of the body's total energy and about half of that is needed to run the pump that maintains healthy levels of sodium and potassium in and around brain cells. A stroke takes away the pump's fuel, called ATP, so neurones and supportive astroglial cells quickly become bloated and dysfunctional. Cells die if the pumps don't start working soon, Dr Kirov says. |
|
193. What's the evidence for aspirin and other antiplatelet drugs? http://www.guardian.co.uk/lifeandstyle/besttreatments/stroke-prevention-evidence-whats-the-evidence- for-aspirin-and-other-antiplatelet-drugs 2009-01-21 15:04:54 Description: There's very good evidence that aspirin and other antiplatelet drugs help prevent strokes. A large number of studies have looked at whether these treatments work for people at high risk of having a stroke or mini-stroke (this includes people who have already had a stroke or mini-stroke, people who have had a heart attack or have another heart condition, and people with diabetes).[1] The results have shown time and time again that antiplatelet drugs can lower people's chances of having a stroke. |
|
194. Fibrates for people who don't have heart disease http://www.guardian.co.uk/lifeandstyle/besttreatments/high-cholesterol-treatments-fibrates-for-peopl e-who-dont-have-heart-disease 2009-01-21 12:07:47 Description: attack or stroke. The only research that has been done involved people who have a moderate risk of heart disease. Fibrates are not used much now, because they don't work as well as statins. To learn more about how doctors work out your risk, see Should I have a cholesterol test? What are they? Fibrates are a type of drug that mainly reduces the amount of triglycerides in your blood, but they also lower cholesterol. Triglycerides are the other main group of fats (lipids) in your blood, besides cholesterol. Doctors now think that having too much of these lipids in your blood can increase your chance of getting heart disease. Fibrates are now used only for people who just have very high levels of triglycerides, or for people who can't take statins for some reason. Doctors sometimes prescribe a fibrate and a statin together. But this doesn't happen often, because you are more likely to get serious side effects if you take them together. You shouldn't take a type of fibrate called gemfibrozil together with a statin.[5] To find out more about triglycerides, see More about cholesterol and triglycerides. If you want to know more about lipid disorders, see Inherited lipid disorders. The names of some of the main fibrates (and brand names) are given below: bezafibrate (Bezalip) ciprofibrate (Modalim) fenofibrate (Lipantil) gemfibrozil (Lopid). When doctors think about treating people with high cholesterol they also look at all the things that can increase a person's risk of having a heart attack or stroke, such as their blood pressure, their age and whether they have diabetes. So, whether you need treatment for high cholesterol will depend on several things, not just your cholesterol level. To learn more, see What will happen to me? How can they help? Taking a fibrate drug can reduce your risk of having a heart attack or stroke.[6] The only study that has been done in people who haven't got heart disease was in those at moderate risk of having a heart attack or stroke. A moderate risk of a heart attack or stroke means there's between a 1 in 10 and 2 in 10 chance of these things happening in the next 10 years. This study found that:[6] Nearly 3 in 100 people who took the drug gemfibrozil had a heart attack or stroke in the next five years. Nearly 4 in 100 people who took a dummy treatment (a placebo) had a heart attack or stroke in the next five years. We don't know how this group of drugs might help people at higher risk of heart attack or stroke, as no studies have been done. Why should they work? Fibrates are thought to work by making an enzyme, called lipoprotein lipase, work harder. An enzyme is a substance that assists a chemical reaction in the body. Lipoprotein lipase breaks down triglycerides in your blood. This means that some of them can be used to give muscles energy and some can be stored in the tissues under your skin, so they can be used later. So if you take a fibrate drug, more of the triglycerides in your blood will be moved to other parts of your body. The role of triglycerides in heart disease is not as clear as that of cholesterol. But there is more and more evidence that having a high level of triglycerides, even if your cholesterol levels are normal, can raise your risk of getting heart disease.[1] [2] [3] [4] If your triglyceride levels fall, your chances of having a heart attack or a stroke should fall too. Can they be harmful? Fibrates can cause muscle pain and damage to your muscles, particularly when they are taken along with statins.You may hear muscle pain called myopathy. In rare cases, the breakdown of muscle tissue can damage your kidneys as well. If you are taking fibrates your doctor may perform regular checks on your blood for a substance called creatine kinase. Creatine kinase is made when muscles break down. However, muscle damage and kidney problems are not common. In one study, only five people out of more than 3,000 had this problem.[7] Four of these people were treated with a fibrate and one was treated with a dummy treatment (placebo) You may have some symptoms of indigestion when you first start taking a fibrate drug.[6] What's the evidence for fibrates for people who don't have heart disease? References Hokanson JE, Austin MA. Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk. 1996; 3 213-219. Assmann G, Schulte H, von Eckardstien A. Hypertriglyceridemia concentration and ischemic heart disease: an 8-year follow-up in the Copenhagen Male Study. American Journal of Cardiology. 1996. 77: 1179-1184. Aberg H, Lithell H, Selinus I et al. Serum triglycerides are a risk factor for myocardial infarction but not for angina pectoris. Results from a 10-year follow-up of Uppsala primary preventive study. Atherosclerosis. 1985; 54: 89-97. Castelli WP. The triglyceride issue: a view from Framingham. American Heart Journal. 1986; 112: 432-437. Medicines and Healthcare products Regulatory Agency. Drug Safety Update November 2007. Fibrates: new prescribing advice. Available at http://www.mhra.gov.uk (accessed on 5 February 2008). Frick MH, Elo O, Haapa K, Heinonen OP, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. New England Journal of Medicine. 1987; 317: 1237-1245. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000; 102: 21-27. Glossary triglycerides Triglycerides are the form in which fat is stored in your body. Triglycerides are made from the fat found in food. They can be used by your body for energy. placebo A placebo is a 'pretend' or dummy treatment that contains no active substances. A placebo is often given to half the people taking part in medical research trials, for comparison with the 'real' treatment. It is made to look and taste identical to the drug treatment being tested, so that people in the studies do not know if they are getting the placebo or the 'real' treatment. Researchers often talk about the 'placebo effect'. This is where patients feel better after having a placebo treatment because they expect to feel better. Tests may indicate that they actually are better. In the same way, people can also get side effects after having a placebo treatment. Drug treatments can also have a 'placebo effect'. This is why, to get a true picture of how well a drug works, it is important to compare it against a placebo treatment. © BMJ Publishing Group Limited ("BMJ Group") 2009 |
|
195. Kidney, Heart Problems May Be Linked http://www.washingtonpost.com/wp-dyn/content/article/2009/01/21/AR2009012101826.html 2009-01-21 12:07:41 Description: George, forge Benediction is what comes at the end of a service. Got that in synagogue. Invoctation is at the beginning. Got this from dictionary.com: a form of prayer invoking God's presence, esp. one said at the beginning of a religious service or public ceremony. |
|
196. Stem cell tests for stroke patients http://www.buteman.co.uk/latest-scottish-news/Stem-cell-tests-for-stroke.4888358.jp 2009-01-18 15:02:49 Description: Published Date: 18 January 2009 Pioneering stem cell treatment could be used for the first time on stroke patients in trials at a Scottish hospital, it was announced. Doctors at Glasgow's Southern General Hospital are preparing to launch tests using cells grown from a single aborted human foetus, following years of work by an English-based research firm. |
|
197. Mayo Clinic Researchers Assess the State of Stroke Telemedicine http://www.istockanalyst.com/article/viewiStockNews/articleid/2961217 2009-01-16 18:01:17 Description: Stroke telemedicine is a lifesaving practice that deserves further advancement, Mayo researchers write in the January 2009 issue of Mayo Clinic Proceedings. Since its inception, stroke telemedicine has developed nationally and internationally as a reliable means of aiding patients. Yet certain key systematic components need to be developed more fully while specific unsettled issues must be resolved. Called a 'telestroke,' a patient with suspected stroke symptoms presents to a local hospital emergency department to undergo a remote stroke assessment by a vascular neurologist at a hub hospital. Described as a consultative modality, stroke telemedicine consults specialists at stroke centers to facilitate the care of patients with acute stroke at underserviced hospitals. In the article, Mayo researchers explain: Telecommunications, which started with the telephone and advanced to audiovisual (AV) communication, has changed the face of medicine not only in remote areas but also in urban areas with a shortage of subspecialties. A surge in the use of telestroke across the United States, Canada and Europe occurred in the late 1990s and early 2000s, resulting in the development of 20 new telestroke networks. The implementation of telemedicine for stroke is a vital piece to the puzzle of creating universal access to emergency care for all patients with stroke, regardless of geographic location or hospital resources. |
|
198. Doctors Re-Examine Blood Thinners to Prevent Strokes http://www.washingtonpost.com/wp-dyn/content/article/2009/01/11/AR2009011100658.html 2009-01-11 09:03:00 Description: SUNDAY, Jan. 11 (HealthDayNews) -- Warfarin is an anticoagulant -- or "blood thinner" -- that's frequently prescribed for people with atrial fibrillation. An estimated 2.2 million Americans have the cardiac condition, which causes the heart's two upper chambers to flutter, rather than beat efficiently. This leaves people vulnerable to a blood clot in the brain that can result in an ischemic stroke, the most common type of stroke. That's where warfarin comes in -- helping to prevent those clots. But, ironically, as use of warfarin has risen in recent years, so has the number of another type of stroke called hemorrhagic stroke, which occurs when a blood vessel ruptures in the brain. That doesn't mean that warfarin should be abandoned -- far from it, experts say. "Decisions about warfarin use should be made by patients after discussion with their doctor," said Dr. Matthew Flaherty, a University of Cincinnati neurologist who led a study published last year in the journal Neurology about the rising rate of brain hemorrhages linked to anticoagulant |
|
199. Sarasota Woman Tells Judge To Imprison Son http://www.msnbc.msn.com/id/28582922/ 2009-01-10 15:03:28 Description: By Todd Ruger -- Sarasota Herald-Tribune Tampa Bay Online updated 10:45 p.m. ET, Fri., Jan. 9, 2009 SARASOTA COUNTY - An 82-year-old woman suffering from the mental and physical fallout of a stroke told a judge Thursday that her son should go to prison for stealing from her. About an hour later, her 61-year-old son was handcuffed, fingerprinted and sent away for two years. "Never in my life would I dream I would be in a position where my firstborn son hurt me," Barbara White said in a letter read aloud in court. |
|
200. How Healthy Is Your State? http://www.parade.com/health/2009/01/how-healthy-is-your-state.html 2009-01-09 12:05:13 Description: Studies have found clear links between where you live and how long you live—discovering patterns even at the neighborhood level. Indeed, some studies link your address with your rate of surviving a stroke or a heart attack. Predictably, you’re better off living near a hospital with experience in handling the situation than you are suffering a heart attack in the middle of nowhere. “Health is not just what happens at the doctor’s office,” says Jarris. “It happens in the community.” |
|
1-10 (8/7/10 - 9/5/10) 11-20 (5/15/10 - 8/5/10) 21-30 (4/4/10 - 5/14/10) 31-40 (3/12/10 - 3/31/10) 41-50 (3/1/10 - 3/12/10) 51-60 (2/4/10 - 2/17/10) 61-70 (1/13/10 - 2/3/10) 71-80 (12/26/09 - 1/11/10) 81-90 (11/17/09 - 12/23/09) 91-100 (10/11/09 - 11/16/09) 101-110 (9/28/09 - 10/10/09) 111-120 (8/25/09 - 9/20/09) 121-130 (7/5/09 - 8/24/09) 131-140 (6/3/09 - 6/27/09) 141-150 (4/21/09 - 5/18/09) 151-160 (4/3/09 - 4/20/09) 161-170 (3/20/09 - 4/2/09) 171-180 (2/19/09 - 3/14/09) 181-190 (2/6/09 - 2/18/09) 191-200 (1/9/09 - 2/3/09) 201-210 (12/26/08 - 1/8/09) 211-220 (12/13/08 - 12/26/08) 221-230 (11/26/08 - 12/12/08) 231-240 (11/18/08 - 11/25/08) 241-250 (10/24/08 - 11/17/08) 251-260 (10/2/08 - 10/22/08) 261-270 (9/15/08 - 10/2/08) 271-280 (8/28/08 - 9/12/08) 281-290 (7/23/08 - 8/27/08) 291-300 (6/23/08 - 7/19/08) 301-310 (6/6/08 - 6/20/08) 311-320 (4/22/08 - 6/6/08) 321-330 (3/17/08 - 4/21/08) 331-340 (2/22/08 - 3/11/08) 341-350 (2/15/08 - 2/22/08) 351-360 (1/30/08 - 2/15/08) 361-370 (1/17/08 - 1/29/08) 371-380 (1/5/08 - 1/17/08) 381-390 (12/11/07 - 1/3/08) 391-400 (11/27/07 - 12/9/07) 401-410 (10/20/07 - 11/26/07) 411-420 (10/3/07 - 10/19/07) 421-430 (9/8/07 - 10/2/07) 431-440 (8/21/07 - 9/7/07) 441-450 (8/1/07 - 8/20/07) 451-460 (7/11/07 - 7/30/07) 461-470 (6/22/07 - 7/8/07) 471-480 (6/3/07 - 6/21/07) 481-490 (5/15/07 - 6/1/07) 491-500 (4/29/07 - 5/14/07) 501-510 (4/11/07 - 4/27/07) 511-520 (4/2/07 - 4/11/07) 521-530 (3/19/07 - 4/2/07) 531-540 (2/22/07 - 3/19/07) 541-550 (2/13/07 - 2/21/07) 551-560 (2/1/07 - 2/12/07) 561-570 (12/12/06 - 2/1/07) 571-580 (9/9/06 - 12/12/06) 581-590 (6/24/06 - 8/31/06) 591-600 (5/4/06 - 6/22/06) 601-610 (2/17/06 - 5/2/06) 611-620 (1/7/06 - 2/17/06) 621-630 (12/8/05 - 1/6/06) 631-640 (11/27/05 - 12/7/05) 641-650 (11/12/05 - 11/26/05) 651-660 (10/12/05 - 11/8/05) 661-670 (9/20/05 - 10/11/05) 671-680 (8/30/05 - 9/16/05) 681-690 (8/10/05 - 8/29/05) 691-700 (7/13/05 - 8/10/05) 701-710 (6/8/05 - 7/12/05) 711-720 (5/18/05 - 6/2/05) 721-730 (4/19/05 - 5/12/05) 731-740 (4/4/05 - 4/18/05) 741-750 (3/8/05 - 3/31/05) 751-760 (2/23/05 - 3/7/05) 761-770 (2/6/05 - 2/22/05) 771-780 (1/20/05 - 2/6/05) 781-790 (1/3/05 - 1/19/05) 791-800 (11/29/04 - 12/28/04) 801-810 (10/24/04 - 11/28/04) 811-820 (9/20/04 - 10/21/04) 821-830 (8/16/04 - 9/19/04) 831-840 (7/26/04 - 8/5/04) 841-850 (6/30/04 - 7/23/04) 851-860 (6/11/04 - 6/30/04) 861-870 (5/10/04 - 6/11/04) 871-880 (4/30/04 - 5/10/04) 881-890 (4/18/04 - 4/29/04) 891-900 (2/25/04 - 4/14/04) 901-910 (10/28/03 - 2/19/04) 911-920 (9/30/03 - 10/28/03) 921-930 (7/14/03 - 9/27/03) 931-940 (5/7/03 - 7/14/03) 941-950 (4/15/03 - 5/6/03) 951-960 (2/14/03 - 4/13/03) 961-970 (1/20/03 - 2/12/03) 971-980 (1/6/03 - 1/17/03) 981-990 (10/16/02 - 12/25/02) 991-1000 (9/19/02 - 10/16/02) 1001-1001 (0/0/ - 0/0/) |